Publications
Detailed Information
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | An, Eunkyung | - |
dc.contributor.author | Ock, Chan Young | - |
dc.contributor.author | Kim, Tae You | - |
dc.contributor.author | Lee, Kyung Hun | - |
dc.contributor.author | Han, Se Won | - |
dc.contributor.author | Im, Seock Ah | - |
dc.contributor.author | Kim, Tae Yong | - |
dc.contributor.author | Liao, Wei Li | - |
dc.contributor.author | Cecchi, Fabiola | - |
dc.contributor.author | Blackler, Adele | - |
dc.contributor.author | Thyparambil, Sheeno | - |
dc.contributor.author | Kim, W. H. | - |
dc.contributor.author | Burrows, Jon | - |
dc.contributor.author | Hembrough, Todd | - |
dc.contributor.author | Catenacci, Daniel V.T. | - |
dc.contributor.author | Oh, Do Youn | - |
dc.contributor.author | Bang, Yung–Jue | - |
dc.date.accessioned | 2021-01-31T11:55:46Z | - |
dc.date.available | 2021-01-31T11:55:46Z | - |
dc.date.created | 2018-07-19 | - |
dc.date.created | 2018-07-19 | - |
dc.date.created | 2018-07-19 | - |
dc.date.created | 2018-07-19 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.citation | Annals of Oncology, Vol.28 No.1, pp.110-115 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 40679 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173143 | - |
dc.description.abstract | Background: A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to accurately distinguish between GC patients who would and would not benefit from anti-HER2 therapies. Patients and methods: GC patients (n = 237), including a subset from the Trastuzumab in GC (ToGA) trial were divided into three groups based on HER2 status and history of treatment with standard chemotherapy or chemotherapy plus trastuzumab. We applied mass spectrometry-based proteomic analysis to quantify HER2 protein expression in formalin-fixed tumor samples. Using HER2 expression as a continuous variable, we defined a predictive protein level cutoff to identify which patients would benefit from trastuzumab. We compared quantitated protein level with clinical outcome and HER2 status as determined by conventional HER2 diagnostics. Results: Quantitative proteomics detected a 115-fold range of HER2 protein expression among patients diagnosed as HER2 positive by standard methods. A protein level of 1825 amol/mg was predicted to determine benefit from the addition of trastuzumab to chemotherapy. Trastuzumab treated patients with HER2 protein levels above this cutoff had twice the median overall survival (OS) of their counterparts below the cutoff (35.0 versus 17.5 months, P = 0.011). Conversely, trastuzumabtreated patients with HER2 levels below the cutoff had outcomes similar to HER2-positive patients treated with chemotherapy. (Progression-free survival = 7.0 versus 6.5 months: P = 0.504; OS = 17.5 versus 12.6 months: P = 0.520). HER2 levels were not prognostic for response to chemotherapy. Conclusions: Proteomic analysis of HER2 expression demonstrated a quantitative cutoff that improves selection of GC patients for trastuzumab as compared with current diagnostic methods. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/annonc/mdw442 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000397239800014 | - |
dc.identifier.scopusid | 2-s2.0-85015809782 | - |
dc.citation.endpage | 115 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 110 | - |
dc.citation.volume | 28 | - |
dc.identifier.sci | 000397239800014 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Tae You | - |
dc.contributor.affiliatedAuthor | Im, Seock Ah | - |
dc.contributor.affiliatedAuthor | Kim, W. H. | - |
dc.contributor.affiliatedAuthor | Oh, Do Youn | - |
dc.contributor.affiliatedAuthor | Bang, Yung–Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | QUANTIFICATION | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | LAPATINIB | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | proteomics | - |
dc.subject.keywordAuthor | trastuzumab | - |
dc.subject.keywordAuthor | molecular characterization | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.